Compare PTGX & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTGX | ASTH |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | 141 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 1.9B |
| IPO Year | 2016 | 2015 |
| Metric | PTGX | ASTH |
|---|---|---|
| Price | $144.72 | $33.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $108.23 | $34.86 |
| AVG Volume (30 Days) | ★ 470.3K | 307.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | 0.69 |
| Revenue | N/A | ★ $519,907,752.00 |
| Revenue This Year | $874.25 | $27.38 |
| Revenue Next Year | N/A | $10.78 |
| P/E Ratio | $61.10 | ★ $49.61 |
| Revenue Growth | N/A | ★ 45.90 |
| 52 Week Low | $62.24 | $18.08 |
| 52 Week High | $160.81 | $51.60 |
| Indicator | PTGX | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 30.25 |
| Support Level | $141.95 | $20.57 |
| Resistance Level | $151.24 | $40.08 |
| Average True Range (ATR) | 4.95 | 1.82 |
| MACD | -0.80 | -0.49 |
| Stochastic Oscillator | 40.44 | 12.23 |
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.